In conclusion, our study shows clearly that drug treatment is sufficient to swiftly correct the liver manifestations of NASH in two different animal models with improved insulin sensitivity, promotion of fatty acid beta-oxidation and reduction of inflammation. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.